Aflatoxin B-1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines

被引:163
|
作者
Mace, K
Aguilar, F
Wang, JS
Vautravers, P
GomezLechon, M
Gonzalez, FJ
Groopman, J
Harris, CC
Pfeifer, AMA
机构
[1] JOHNS HOPKINS UNIV,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205
[2] HOSP UNIV LA FE,UNIDAD HEPATOL EXPT,VALENCIA 46009,SPAIN
[3] NCI,MOL CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892
[4] NCI,HUMAN CARCINOGENESIS LAB,DIV BASIC SCI,BETHESDA,MD 20892
关键词
D O I
10.1093/carcin/18.7.1291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidemiological evidence has been supporting a relationship between dietary aflatoxin B-1 (AFB(1)) exposure, development of human primary hepatocellular carcinoma (HCC) and mutations in the p53 tumor suppressor gene. However, the correlation between the observed p53 mutations, the AFB(1) DNA adducts and their activation pathways has not been elucidated. Development of relevant cellular in vitro models, taking into account species and tissue specificity, could significantly contribute to the knowledge of cytotoxicity and genotoxicity mechanisms of chemical procarcinogens, such as AFB(1), in humans. For this purpose a non-tumorigenic SV40-immortalized human liver epithelial cell line (THLE cells) which retained most of the phase II enzymes, but had markedly reduced phase I activities was used for stable expression of the human CYP1A2, CYP2A6, CYP2B6 and CYP3A4 cDNA. The four genetically engineered cell lines (T5-1A2, T5-2A6, T5-2B6 and T5-3A4) produced high levels of the specific CYP450 proteins and showed comparable or higher catalytic activities related to the CYP450 expression when compared to human hepatocytes. The T5-1A2, T5-2A6, T5-2B6 and T5-3A4 cell lines exhibited a very high sensitivity to the cytotoxic effects of AFB(1) and were approximately 125-, 2-, 2- and 15-fold, respectively, more sensitive than the control T5-neo cells, transfected with an expressing vector which does not contain CYP450 cDNA. In the CYP450-expressing cells, nanomolar doses of AFB(1)-induced DNA, adduct formation including AFB(1)-N-7-guanine, -pyrimidyl and -diol adducts. In addition, the T5-1A2 cells showed AFM(1)-DNA adducts. At similar levels of total DNA adducts, both the T5-1A2 and T5-3A4 cells showed, at codon 249 of the p53 gene, AGG to AGT transversions at a relative frequency of 15x10(-6). In contrast, only the T5-3A4 cells showed CCC to ACC transversion at codon 250 at a high frequency, whereas the second most frequent mutations found in the T5-1A2 cells were C to T transitions at the first and second position of the codon 250. No significant AFB(1)-induced p53 mutations could be detected in the T5-2A6 cells. Therefore, the differential expression of specific CYP450 genes in human hepatocytes can modulate the cytotoxicity, DNA adduct levels and frequency of p53 mutations produced by AFB(1).
引用
收藏
页码:1291 / 1297
页数:7
相关论文
共 50 条
  • [21] Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status
    Martelli, Laura
    Di Mario, Francesco
    Botti, Paolo
    Ragazzi, Eugenio
    Martelli, Mario
    Kelland, Lloyd
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (01) : 20 - 27
  • [22] Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients
    Zhang, Yu-Jing
    Rossner, Pavel, Jr.
    Chen, Yu
    Agrawal, Meenakshi
    Wang, Qiao
    Wang, Lillian
    Ahsan, Habibul
    Yu, Ming-Whei
    Lee, Po-Huang
    Santella, Regina M.
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) : 985 - 991
  • [23] JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin
    Fokkema, E
    Groen, HJM
    Helder, MN
    de Vries, EGE
    Meijer, C
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (11) : 1989 - 1996
  • [24] Low-dose microcystin-LR antagonizes aflatoxin B1 induced hepatocarcinogenesis through decreasing cytochrome P450 1A2 expression and aflatoxin B1-DNA adduct generation
    Wang, Lingqiao
    He, Lixiong
    Zeng, Hui
    Fu, Wenjuan
    Wang, Jia
    Tan, Yao
    Zheng, Chuanfen
    Qiu, Zhiqun
    Luo, Jiaohua
    Lv, Chen
    Huang, Yujing
    Shu, Weiqun
    CHEMOSPHERE, 2020, 248
  • [25] Low-dose microcystin-LR antagonizes aflatoxin B1 induced hepatocarcinogenesis through decreasing cytochrome P450 1A2 expression and aflatoxin B1-DNA adduct generation
    Wang L.
    He L.
    Zeng H.
    Fu W.
    Wang J.
    Tan Y.
    Zheng C.
    Qiu Z.
    Luo J.
    Lv C.
    Huang Y.
    Shu W.
    Chemosphere, 2020, 248
  • [26] P53 MUTATIONS ARE ABSENT FROM CARCINOGEN-INDUCED MOUSE-LIVER TUMORS BUT OCCUR IN CELL-LINES ESTABLISHED FROM THESE TUMORS
    KRESS, S
    KONIG, J
    SCHWEIZER, J
    LOHRKE, H
    BAUERHOFMANN, R
    SCHWARZ, M
    MOLECULAR CARCINOGENESIS, 1992, 6 (02) : 148 - 158
  • [27] DIMINISHED CAPACITY FOR P53 IN MEDIATING A RADIATION-INDUCED G(1) ARREST IN ESTABLISHED HUMAN TUMOR-CELL LINES
    LI, CY
    NAGASAWA, H
    DAHLBERG, WK
    LITTLE, JB
    ONCOGENE, 1995, 11 (09) : 1885 - 1892
  • [28] Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue
    Ko, Y
    Abel, J
    Harth, V
    Bröde, P
    Antony, C
    Donat, S
    Fischer, HP
    Ortiz-Pallardo, ME
    Thier, R
    Sachinidis, A
    Vetter, H
    Bolt, HM
    Herberhold, C
    Brüning, T
    CANCER RESEARCH, 2001, 61 (11) : 4398 - 4404
  • [29] Cytochrome P450 2A13 enhances the sensitivity of human bronchial epithelial cells to aflatoxin B1-induced DNA damage
    Yang, Xuejiao
    Zhang, Zhan
    Wang, Xichen
    Wang, Yun
    Zhang, Xiaoming
    Lu, Huiyuan
    Wang, Shou-Lin
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2013, 270 (02) : 114 - 121
  • [30] Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations
    Kawasaki, T
    Tomita, Y
    Bilim, V
    Takeda, M
    Takahashi, K
    Kumanishi, T
    INTERNATIONAL JOURNAL OF CANCER, 1996, 68 (04) : 501 - 505